Biomarin Pharma Reports Earnings of $0.38, Surpassing Expectations with Strong Profits

According to Biomarin Pharma's (NASDAQ: BMRN) report, the earnings per share for the third quarter were $0.91, exceeding analysts' expectations of $0.53 by $0.38. The reported earnings for this quarter were determined to be $746M, while analyst expectations were $703.14M.

For the fiscal year 2024, Biomarin Pharma has projected earnings per share to be between $3.25 and $3.35. Analyst estimates were previously stated at $3.22. The company’s revenue for fiscal year 2024 is expected to be between $2.79B and $2.83B, with analyst forecasts of $2.80B.

Biomarin Pharma's stock closed the day at $69.91, indicating a decline of 16.97% over the past three months. Over the last 12 months, the stock has decreased by 13.67%. In the last 90 days, Biomarin Pharma experienced 15 positive earnings per share reports and 2 negative ones.

InvestingPro rates Biomarin Pharma’s financial health as "Good Performance." To review the latest earnings reports and all financial information about Biomarin Pharma, please check here. Stay updated on all developments related to financial statements by visiting the Investing.com Earnings Calendar.